Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III REACH-2 study of Cyramza meets primary endpoint

April 5, 2018

FDA and EMA accept regulatory submissions for dacomitinib

April 5, 2018

Novel orally bioavailable rohitukine derivative shows promise in xenograft cancer models

April 5, 2018

Triple combination program for the treatment of cystic fibrosis receives FDA fast track designation

April 5, 2018

Immunic initiates phase III CALDOSE-1 study of IMU-838

April 5, 2018

Phase III study evaluates ASTX-727 versus intravenous decitabine in patients with MDS and CMML

April 5, 2018

Corvus Pharmaceuticals initiates phase I study of CPI-006 in patients with advanced solid tumors

April 5, 2018

Nkx-6.1 identified as diagnostic marker of lung and pancreatic NETs

April 4, 2018

Sellas reports interim phase IIb data on Herceptin + NeuVax in breast cancer

April 4, 2018

SOX-9 unveiled as potential prognostic marker in lymphoma

April 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...